Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 2766 for

Edit search filters
  1. Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  3. Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

    Jacksonville, FL

  4. INHERIT Study to Evaluate Proactive Genetic Testing in Cancer Patients

    Jacksonville, FL

  5. Phase 1/2 Study Of MRTX1719 In Solid Tumors With MTAP Deletion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

    Rochester, MN

  7. The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

    Rochester, MN

  8. Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

    Rochester, MN

  9. Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

    Rochester, MN

  10. Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

    Rochester, MN

.

Mayo Clinic Footer